Dataset Information


No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.

ABSTRACT: Concern has been expressed that tenofovir-containing regimens may have reduced effectiveness in the treatment of human immunodeficiency virus type 1 (HIV-1) subtype C infections because of a propensity for these viruses to develop a key tenofovir-associated resistance mutation. We evaluated whether subtype influenced rates of virological failure in a cohort of 8746 patients from the United Kingdom who received a standard tenofovir-containing first-line regimen and were followed for a median of 3.3 years. In unadjusted analyses, the rate of failure was approximately 2-fold higher among patients infected with subtype C virus as compared to those with subtype B virus (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.50-2.31; P < .001). However, the increased risk was greatly attenuated in analyses adjusting for demographic and clinical factors (adjusted HR, 1.14; 95% CI, .83-1.58; P = .41). There were no differences between subtypes C and subtypes non-B and non-C in either univariate or multivariate analysis. These observations imply there is no intrinsic effect of viral subtype on the efficacy of tenofovir-containing regimens.


PROVIDER: S-EPMC5079361 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC6519052 | BioStudies
2017-01-01 | S-EPMC5427983 | BioStudies
2015-01-01 | S-EPMC4425827 | BioStudies
1000-01-01 | S-EPMC4943563 | BioStudies
2011-01-01 | S-EPMC3223170 | BioStudies
1000-01-01 | S-EPMC4725384 | BioStudies
2017-01-01 | S-EPMC5421555 | BioStudies
2018-01-01 | S-EPMC5906523 | BioStudies
2018-01-01 | S-EPMC5766130 | BioStudies
2016-01-01 | S-EPMC4882399 | BioStudies